Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or complete cessation of blood flow to a portion of the myocardium. Myocardial infarction may be “silent,” and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death. Most myocardial infarctions are due to underlying coronary artery disease, the leading cause of death in the United States. In myocardial infarction, there are 60+ drugs in different phases of development.
DelveInsight adds a new edition to its newsletter series that pivots around the myocardial infarction space. The newsletter offers a complete picture of the myocardial infarction market landscape, ongoing clinical trials, pipeline therapies that are expected to transform the myocardial infarction market in the coming decade.
Gain rich insights into myocardial infarction epidemiology details, current treatment therapies, details of the latest news and happenings, mergers and collaborations, critical pharmaceuticals involved, licensing deals along with events and top-level conferences taking place in the myocardial infarction field.
Get a sneak peek of the myocardial infarction pipeline therapies, clinical trials, deals & tie-ups, and upcoming world-class conferences, as well as track all the recent updates in the myocardial infarction market.
Interested in knowing more about what upcoming years hold for the myocardial infarction market and how pharma companies work to push drug development? Download our Newsletter by simply filling up the form on the right.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Unmet needs
- Key Companies
- Market insights
- Clinical trials
- Pipeline drugs
- Collaborations and deals in the domain
- R&D in the field
- Top conferences
- Support from International organizations